Wong, Sandy W.

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy

Thiruvengadam, S. K., Sheng, Y., Huang, C.-Y., Bylsma, S., Lo, M., Kennedy, V., Natsuhara, K., Martin, T., Wolf, J., Shah, N., et al. (2022) · Blood Advances

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 131

Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).

Mailankody, S., Jakubowiak, A. J., Htut, M., Costa, L. J., Lee, K., Ganguly, S., Kaufman, J. L., Siegel, D. S. D., Bensinger, W., Cota, M., et al. (2020) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 126